{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T05:52:16Z","timestamp":1781502736254,"version":"3.54.1"},"reference-count":133,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,14]]},"DOI":"10.7759\/cureus.110851","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:58:48Z","timestamp":1781499528000},"source":"Crossref","is-referenced-by-count":0,"title":["Network Pharmacology and Molecular Docking for Natural Product-Based Therapies in Gallbladder and Biliary Tract Cancers: Workflows, Pitfalls, and Translational Opportunities"],"prefix":"10.7759","author":[{"given":"Sushant S","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajni","family":"Rathore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harsimranjit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shalika","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ramkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1111\/liv.16199","article-title":"Global burden, trends, and inequalities of gallbladder and biliary tract cancer, 1990-2021: a decomposition and age-period-cohort analysis","volume":"45","author":"Lei S","year":"2025","unstructured":"Lei S, Huang G, Li X, Xi P, Yao Z, Lin X. Global burden, trends, and inequalities of gallbladder and biliary tract cancer, 1990-2021: a decomposition and age-period-cohort analysis. Liver Int. 2025, 45:e16199. 10.1111\/liv.16199","journal-title":"Liver Int"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2016.03.004","article-title":"The inflammatory inception of gallbladder cancer","volume":"1865","author":"Espinoza JA","year":"2016","unstructured":"Espinoza JA, Bizama C, Garc\u00eda P, et al.. The inflammatory inception of gallbladder cancer. Biochim Biophys Acta. 2016, 1865:245-54. 10.1016\/j.bbcan.2016.03.004","journal-title":"Biochim Biophys Acta"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-17880-4","article-title":"Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate","volume":"11","author":"Pandey A","year":"2020","unstructured":"Pandey A, Stawiski EW, Durinck S, et al.. Integrated genomic analysis reveals mutated ELF3 as a potential gallbladder cancer vaccine candidate. Nat Commun. 2020, 11:4225. 10.1038\/s41467-020-17880-4","journal-title":"Nat Commun"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2018.08.18","article-title":"Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets","volume":"10","author":"Weinberg BA","year":"2019","unstructured":"Weinberg BA, Xiu J, Lindberg MR, et al.. Molecular profiling of biliary cancers reveals distinct molecular alterations and potential therapeutic targets. J Gastrointest Oncol. 2019, 10:652-62. 10.21037\/jgo.2018.08.18","journal-title":"J Gastrointest Oncol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.2147\/CLEP.S37357","article-title":"Gallbladder cancer: epidemiology and outcome","volume":"6","author":"Hundal R","year":"2014","unstructured":"Hundal R, Shaffer EA. Gallbladder cancer: epidemiology and outcome. Clin Epidemiol. 2014, 6:99-109. 10.2147\/CLEP.S37357","journal-title":"Clin Epidemiol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1183619","article-title":"Gallbladder cancer: current and future treatment options","volume":"14","author":"Zhou Y","year":"2023","unstructured":"Zhou Y, Yuan K, Yang Y, et al.. Gallbladder cancer: current and future treatment options. Front Pharmacol. 2023, 14:1183619. 10.3389\/fphar.2023.1183619","journal-title":"Front Pharmacol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.70208","article-title":"Systemic therapy for advanced biliary tract cancers in 2026: current standard of care and emerging therapeutic strategies","volume":"41","author":"Yoon H","year":"2026","unstructured":"Yoon H, Yoo C. Systemic therapy for advanced biliary tract cancers in 2026: current standard of care and emerging therapeutic strategies. J Gastroenterol Hepatol. 2026, 41:516-31. 10.1111\/jgh.70208","journal-title":"J Gastroenterol Hepatol"},{"key":"ref8","article-title":"Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study","volume":"9","author":"Oh DY","year":"2024","unstructured":"Oh DY, He AR, Bouattour M, et al.. Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study. Lancet Gastroenterol Hepatol. 2024, 9:694-704.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref9","article-title":"Three-year follow-up data from KEYNOTE-966: pembrolizumab (pembro) plus gemcitabine and cisplatin (gem\/cis) compared with gem\/cis alone for patients (pts) with advanced biliary tract cancer (BTC)","volume":"42","author":"Finn RS","year":"2024","unstructured":"Finn RS, Ueno M, Yoo C, et al.. Three-year follow-up data from KEYNOTE-966: pembrolizumab (pembro) plus gemcitabine and cisplatin (gem\/cis) compared with gem\/cis alone for patients (pts) with advanced biliary tract cancer (BTC). J Clin Oncol. 2024, 42:4093-4093.","journal-title":"J Clin Oncol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.21037\/jgo-2025-83","article-title":"Recent advancements in systemic therapy for biliary tract cancers: a literature review","volume":"16","author":"Hussain MM","year":"2025","unstructured":"Hussain MM, Qammar S, Wang JM, Zhai AQ, Li FY, Hu HJ. Recent advancements in systemic therapy for biliary tract cancers: a literature review. J Gastrointest Oncol. 2025, 16:2402-29. 10.21037\/jgo-2025-83","journal-title":"J Gastrointest Oncol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2024.101170","article-title":"New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe","volume":"50","author":"Rimassa L","year":"2025","unstructured":"Rimassa L, Lamarca A, O'Kane GM, et al.. New systemic treatment paradigms in advanced biliary tract cancer and variations in patient access across Europe. Lancet Reg Health Eur. 2025, 50:101170. 10.1016\/j.lanepe.2024.101170","journal-title":"Lancet Reg Health Eur"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s13659-020-00293-7","article-title":"Natural products in cancer therapy: past, present and future","volume":"11","author":"Huang M","year":"2021","unstructured":"Huang M, Lu JJ, Ding J. Natural products in cancer therapy: past, present and future. Nat Prod Bioprospect. 2021, 11:5-13. 10.1007\/s13659-020-00293-7","journal-title":"Nat Prod Bioprospect"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70014","article-title":"Natural products and cancer: from drug discovery to prevention and therapy","volume":"182","author":"Izzo AA","year":"2025","unstructured":"Izzo AA, Stefanska B. Natural products and cancer: from drug discovery to prevention and therapy. Br J Pharmacol. 2025, 182:2069-74. 10.1111\/bph.70014","journal-title":"Br J Pharmacol"},{"key":"ref14","article-title":"Therapeutic role of phytochemicals in gallbladder cancer: pharmacological activity and associated molecular mechanisms","volume":"4","author":"Patel K","year":"2025","unstructured":"Patel K, Patel DK. Therapeutic role of phytochemicals in gallbladder cancer: pharmacological activity and associated molecular mechanisms. J Enterocolitis. 2025, 4:1-8.","journal-title":"J Enterocolitis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3390\/antiox12112012","article-title":"Phytochemicals target multiple metabolic pathways in cancer","volume":"12","author":"Shuvalov O","year":"2023","unstructured":"Shuvalov O, Kirdeeva Y, Daks A, Fedorova O, Parfenyev S, Simon HU, Barlev NA. Phytochemicals target multiple metabolic pathways in cancer. Antioxidants (Basel). 2023, 12:2012. 10.3390\/antiox12112012","journal-title":"Antioxidants (Basel)"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/nchembio.118","article-title":"Network pharmacology: the next paradigm in drug discovery","volume":"4","author":"Hopkins AL","year":"2008","unstructured":"Hopkins AL. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol. 2008, 4:682-90. 10.1038\/nchembio.118","journal-title":"Nat Chem Biol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40160-2","article-title":"Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management","volume":"13","author":"Agu PC","year":"2023","unstructured":"Agu PC, Afiukwa CA, Orji OU, et al.. Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management. Sci Rep. 2023, 13:13398. 10.1038\/s41598-023-40160-2","journal-title":"Sci Rep"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2016.06.018","article-title":"Network pharmacology of cancer: from understanding of complex interactomes to the design of multi-target specific therapeutics from nature","volume":"111","author":"Poornima P","year":"2016","unstructured":"Poornima P, Kumar JD, Zhao Q, Blunder M, Efferth T. Network pharmacology of cancer: from understanding of complex interactomes to the design of multi-target specific therapeutics from nature. Pharmacol Res. 2016, 111:290-302. 10.1016\/j.phrs.2016.06.018","journal-title":"Pharmacol Res"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1038\/nrd1549","article-title":"Docking and scoring in virtual screening for drug discovery: methods and applications","volume":"3","author":"Kitchen DB","year":"2004","unstructured":"Kitchen DB, Decornez H, Furr JR, Bajorath J. Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov. 2004, 3:935-49. 10.1038\/nrd1549","journal-title":"Nat Rev Drug Discov"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.1002537","article-title":"Editorial: Network pharmacology and traditional medicine: setting the new standards by combining In silico and experimental work","volume":"13","author":"Wang X","year":"2022","unstructured":"Wang X, Hu Y, Zhou X, Li S. Editorial: Network pharmacology and traditional medicine: setting the new standards by combining In silico and experimental work. Front Pharmacol. 2022, 13:1002537. 10.3389\/fphar.2022.1002537","journal-title":"Front Pharmacol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/1646905","article-title":"Applications of network pharmacology in traditional Chinese medicine research","volume":"2020","author":"Zhou Z","year":"2020","unstructured":"Zhou Z, Chen B, Chen S, et al.. Applications of network pharmacology in traditional Chinese medicine research. Evid Based Complement Alternat Med. 2020, 2020:1646905. 10.1155\/2020\/1646905","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S157092","article-title":"Biliary tract cancers: current knowledge, clinical candidates and future challenges","volume":"11","author":"Tariq NU","year":"2019","unstructured":"Tariq NU, McNamara MG, Valle JW. Biliary tract cancers: current knowledge, clinical candidates and future challenges. Cancer Manag Res. 2019, 11:2623-42. 10.2147\/CMAR.S157092","journal-title":"Cancer Manag Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.5114\/ceh.2019.85166","article-title":"Epidemiology of gallbladder cancer","volume":"5","author":"Rawla P","year":"2019","unstructured":"Rawla P, Sunkara T, Thandra KC, Barsouk A. Epidemiology of gallbladder cancer. Clin Exp Hepatol. 2019, 5:93-102. 10.5114\/ceh.2019.85166","journal-title":"Clin Exp Hepatol"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1159\/000453013","article-title":"Epidemiology and risk factors of cholangiocarcinoma","volume":"32","author":"Kirstein MM","year":"2016","unstructured":"Kirstein MM, Vogel A. Epidemiology and risk factors of cholangiocarcinoma. Visc Med. 2016, 32:395-400. 10.1159\/000453013","journal-title":"Visc Med"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-022-00398-y","article-title":"Gallbladder cancer","volume":"8","author":"Roa JC","year":"2022","unstructured":"Roa JC, Garc\u00eda P, Kapoor VK, Maithel SK, Javle M, Koshiol J. Gallbladder cancer. Nat Rev Dis Primers. 2022, 8:69. 10.1038\/s41572-022-00398-y","journal-title":"Nat Rev Dis Primers"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.hpb.2016.05.016","article-title":"Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US extra-hepatic biliary malignancy consortium","volume":"18","author":"Margonis GA","year":"2016","unstructured":"Margonis GA, Gani F, Buettner S, et al.. Rates and patterns of recurrence after curative intent resection for gallbladder cancer: a multi-institution analysis from the US extra-hepatic biliary malignancy consortium. HPB (Oxford). 2016, 18:872-8. 10.1016\/j.hpb.2016.05.016","journal-title":"HPB (Oxford)"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184446","article-title":"Targetable molecular alterations in the treatment of biliary tract cancers: an overview of the available treatments","volume":"15","author":"Valery M","year":"2023","unstructured":"Valery M, Vasseur D, Fachinetti F, et al.. Targetable molecular alterations in the treatment of biliary tract cancers: an overview of the available treatments. Cancers (Basel). 2023, 15:4446. 10.3390\/cancers15184446","journal-title":"Cancers (Basel)"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4143\/crt.2014.308","article-title":"Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review","volume":"47","author":"Park JO","year":"2015","unstructured":"Park JO, Oh DY, Hsu C, et al.. Gemcitabine plus cisplatin for advanced biliary tract cancer: a systematic review. Cancer Res Treat. 2015, 47:343-61. 10.4143\/crt.2014.308","journal-title":"Cancer Res Treat"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.5009\/gnl210346","article-title":"Real-world outcomes of gemcitabine, cisplatin, and nab-paclitaxel chemotherapy regimen for advanced biliary tract cancer: a propensity score-matched analysis","volume":"16","author":"Jung K","year":"2022","unstructured":"Jung K, Park J, Jung JH, Lee JC, Kim J, Hwang JH. Real-world outcomes of gemcitabine, cisplatin, and nab-paclitaxel chemotherapy regimen for advanced biliary tract cancer: a propensity score-matched analysis. Gut Liver. 2022, 16:798-805. 10.5009\/gnl210346","journal-title":"Gut Liver"},{"key":"ref30","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(23)00727-4","article-title":"Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"401","author":"Kelley RK","year":"2023","unstructured":"Kelley RK, Ueno M, Yoo C, et al.. Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023, 401:1853-65.","journal-title":"Lancet"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.21037\/cco-22-93","article-title":"Targeted therapies in advanced biliary tract cancers-a narrative review","volume":"12","author":"LaPelusa M","year":"2023","unstructured":"LaPelusa M, Heumann T, Goff L, Agarwal R. Targeted therapies in advanced biliary tract cancers-a narrative review. Chin Clin Oncol. 2023, 12:14. 10.21037\/cco-22-93","journal-title":"Chin Clin Oncol"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.21037\/atm.2019.08.67","article-title":"Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice","volume":"7","author":"Lin J","year":"2019","unstructured":"Lin J, Dong K, Bai Y, et al.. Precision oncology for gallbladder cancer: insights from genetic alterations and clinical practice. Ann Transl Med. 2019, 7:467. 10.21037\/atm.2019.08.67","journal-title":"Ann Transl Med"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2018.01.007","article-title":"Desmoplastic tumor microenvironment and immunotherapy in cholangiocarcinoma","volume":"4","author":"H\u00f8gdall D","year":"2018","unstructured":"H\u00f8gdall D, Lewinska M, Andersen JB. Desmoplastic tumor microenvironment and immunotherapy in cholangiocarcinoma. Trends Cancer. 2018, 4:239-55. 10.1016\/j.trecan.2018.01.007","journal-title":"Trends Cancer"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1002\/hep.26762","article-title":"Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting","volume":"59","author":"Sirica AE","year":"2014","unstructured":"Sirica AE, Gores GJ. Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology. 2014, 59:2397-402. 10.1002\/hep.26762","journal-title":"Hepatology"},{"key":"ref35","article-title":"Chemotherapy dosing in the setting of liver dysfunction","volume":"19","author":"Eklund JW","year":"2005","unstructured":"Eklund JW, Trifilio S, Mulcahy MF. Chemotherapy dosing in the setting of liver dysfunction. Oncology. 2005, 19:1057-63.","journal-title":"Oncology"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.21037\/jgo.2016.09.17","article-title":"Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function","volume":"8","author":"Gong J","year":"2017","unstructured":"Gong J, Cho M, Fakih M. Chemotherapy in patients with hepatobiliary cancers and abnormal hepatic function. J Gastrointest Oncol. 2017, 8:314-23. 10.21037\/jgo.2016.09.17","journal-title":"J Gastrointest Oncol"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.4291\/wjgp.v1.i1.12","article-title":"Molecular mechanisms of cholangiocarcinoma","volume":"1","author":"Fava G","year":"2010","unstructured":"Fava G. Molecular mechanisms of cholangiocarcinoma. World J Gastrointest Pathophysiol. 2010, 1:12-22. 10.4291\/wjgp.v1.i1.12","journal-title":"World J Gastrointest Pathophysiol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.3390\/cells11142209","article-title":"The role of natural products and their multitargeted approach to treat solid cancer","volume":"11","author":"Muhammad N","year":"2022","unstructured":"Muhammad N, Usmani D, Tarique M, et al.. The role of natural products and their multitargeted approach to treat solid cancer. Cells. 2022, 11:2209. 10.3390\/cells11142209","journal-title":"Cells"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbx045","article-title":"In silico polypharmacology of natural products","volume":"19","author":"Fang J","year":"2018","unstructured":"Fang J, Liu C, Wang Q, Lin P, Cheng F. In silico polypharmacology of natural products. Brief Bioinform. 2018, 19:1153-71. 10.1093\/bib\/bbx045","journal-title":"Brief Bioinform"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.3390\/nu8110628","article-title":"Unraveling the anticancer effect of curcumin and resveratrol","volume":"8","author":"Pavan AR","year":"2016","unstructured":"Pavan AR, Silva GD, Jornada DH, Chiba DE, Fernandes GF, Man Chin C, Dos Santos JL. Unraveling the anticancer effect of curcumin and resveratrol. Nutrients. 2016, 8:628. 10.3390\/nu8110628","journal-title":"Nutrients"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0114851","article-title":"Baicalein inhibits progression of gallbladder cancer cells by downregulating ZFX","volume":"10","author":"Liu TY","year":"2015","unstructured":"Liu TY, Gong W, Tan ZJ, et al.. Baicalein inhibits progression of gallbladder cancer cells by downregulating ZFX. PLoS One. 2015, 10:e0114851. 10.1371\/journal.pone.0114851","journal-title":"PLoS One"},{"key":"ref42","article-title":"Targeting gallbladder cancer: hyaluronan sensitizes cancer cells to chemo-therapeutics","volume":"8","author":"Ma M","year":"2015","unstructured":"Ma M, Weng M, Zhang M, Qin Y, Gong W, Quan Z. Targeting gallbladder cancer: hyaluronan sensitizes cancer cells to chemo-therapeutics. Int J Clin Exp Pathol. 2015, 8:1822-5.","journal-title":"Int J Clin Exp Pathol"},{"key":"ref43","article-title":"The role of PI3K\/AKT signaling pathway in gallbladder carcinoma","volume":"14","author":"Wu Z","year":"2022","unstructured":"Wu Z, Yu X, Zhang S, He Y, Guo W. The role of PI3K\/AKT signaling pathway in gallbladder carcinoma. Am J Transl Res. 2022, 14:4426-42.","journal-title":"Am J Transl Res"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.101736","article-title":"Pre-clinical evaluation of Shilajit in cancer: a systematic review","volume":"18","author":"Das SS","year":"2026","unstructured":"Das SS, Ramkumar M, Singh H, Sharma S. Pre-clinical evaluation of Shilajit in cancer: a systematic review. Cureus. 2026, 18:e101736. 10.7759\/cureus.101736","journal-title":"Cureus"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01996-8","article-title":"Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment","volume":"11","author":"Kloskowski T","year":"2021","unstructured":"Kloskowski T, Szeliski K, Krzeszowiak K, et al.. Mumio (Shilajit) as a potential chemotherapeutic for the urinary bladder cancer treatment. Sci Rep. 2021, 11:22614. 10.1038\/s41598-021-01996-8","journal-title":"Sci Rep"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1016\/j.sjbs.2022.103393","article-title":"Shilajit potentiates the effect of chemotherapeutic drugs and mitigates metastasis induced liver and kidney damages in osteosarcoma rats","volume":"29","author":"Jambi EJ","year":"2022","unstructured":"Jambi EJ, Abdulaziz Alshubaily F. Shilajit potentiates the effect of chemotherapeutic drugs and mitigates metastasis induced liver and kidney damages in osteosarcoma rats. Saudi J Biol Sci. 2022, 29:103393. 10.1016\/j.sjbs.2022.103393","journal-title":"Saudi J Biol Sci"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1002\/ame2.12165","article-title":"Cancer models in preclinical research: a chronicle review of advancement in effective cancer research","volume":"4","author":"Sajjad H","year":"2021","unstructured":"Sajjad H, Imtiaz S, Noor T, Siddiqui YH, Sajjad A, Zia M. Cancer models in preclinical research: a chronicle review of advancement in effective cancer research. Animal Model Exp Med. 2021, 4:87-103. 10.1002\/ame2.12165","journal-title":"Animal Model Exp Med"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1124\/pharmrev.120.000106","article-title":"Modeling pharmacokinetic natural product-drug interactions for decision-making: a NaPDI center recommended approach","volume":"73","author":"Cox EJ","year":"2021","unstructured":"Cox EJ, Tian DD, Clarke JD, et al.. Modeling pharmacokinetic natural product-drug interactions for decision-making: a NaPDI center recommended approach. Pharmacol Rev. 2021, 73:847-59. 10.1124\/pharmrev.120.000106","journal-title":"Pharmacol Rev"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1208\/s12249-013-9966-9","article-title":"Batch-to-batch quality consistency evaluation of botanical drug products using multivariate statistical analysis of the chromatographic fingerprint","volume":"14","author":"Xiong H","year":"2013","unstructured":"Xiong H, Yu LX, Qu H. Batch-to-batch quality consistency evaluation of botanical drug products using multivariate statistical analysis of the chromatographic fingerprint. AAPS PharmSciTech. 2013, 14:802-10. 10.1208\/s12249-013-9966-9","journal-title":"AAPS PharmSciTech"},{"key":"ref50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1410942","article-title":"Network pharmacology: an efficient but underutilized approach in oral, head and neck cancer therapy-a review","volume":"15","author":"Muthuramalingam P","year":"2024","unstructured":"Muthuramalingam P, Jeyasri R, Varadharajan V, et al.. Network pharmacology: an efficient but underutilized approach in oral, head and neck cancer therapy-a review. Front Pharmacol. 2024, 15:1410942. 10.3389\/fphar.2024.1410942","journal-title":"Front Pharmacol"},{"key":"ref51","doi-asserted-by":"publisher","DOI":"10.2174\/13816128113199990470","article-title":"Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles","volume":"20","author":"Tang J","year":"2014","unstructured":"Tang J, Aittokallio T. Network pharmacology strategies toward multi-target anticancer therapies: from computational models to experimental design principles. Curr Pharm Des. 2014, 20:23-36. 10.2174\/13816128113199990470","journal-title":"Curr Pharm Des"},{"key":"ref52","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-801814-9.00005-2","article-title":"Network pharmacology","author":"Chandran U","year":"2017","unstructured":"Chandran U, Mehendale N, Patil S, Chaguturu R, Patwardhan B. Network pharmacology. Innovative Approaches in Drug Discovery. Academic Press, Boston, MA; 2017. 127-64. 10.1016\/B978-0-12-801814-9.00005-2"},{"key":"ref53","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2014.08.006","article-title":"Multi-target approach for natural products in inflammation","volume":"19","author":"Koeberle A","year":"2014","unstructured":"Koeberle A, Werz O. Multi-target approach for natural products in inflammation. Drug Discov Today. 2014, 19:1871-82. 10.1016\/j.drudis.2014.08.006","journal-title":"Drug Discov Today"},{"key":"ref54","doi-asserted-by":"publisher","DOI":"10.3390\/medicines6010006","article-title":"The multitarget activity of natural extracts on cancer: synergy and xenohormesis","volume":"6","author":"Herranz-L\u00f3pez M","year":"2018","unstructured":"Herranz-L\u00f3pez M, Losada-Echeberr\u00eda M, Barraj\u00f3n-Catal\u00e1n E. The multitarget activity of natural extracts on cancer: synergy and xenohormesis. Medicines (Basel). 2018, 6:6. 10.3390\/medicines6010006","journal-title":"Medicines (Basel)"},{"key":"ref55","doi-asserted-by":"publisher","DOI":"10.1016\/j.joim.2022.09.004","article-title":"Methodology of network pharmacology for research on Chinese herbal medicine against COVID-19: a review","volume":"20","author":"Wang YX","year":"2022","unstructured":"Wang YX, Yang Z, Wang WX, et al.. Methodology of network pharmacology for research on Chinese herbal medicine against COVID-19: a review. J Integr Med. 2022, 20:477-87. 10.1016\/j.joim.2022.09.004","journal-title":"J Integr Med"},{"key":"ref56","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/621423","article-title":"Network pharmacology: a new approach for chinese herbal medicine research","volume":"2013","author":"Zhang GB","year":"2013","unstructured":"Zhang GB, Li QY, Chen QL, Su SB. Network pharmacology: a new approach for chinese herbal medicine research. Evid Based Complement Alternat Med. 2013, 2013:621423. 10.1155\/2013\/621423","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref57","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-023-04254-8","article-title":"Network pharmacology-based strategy to investigate the bioactive ingredients and molecular mechanism of Evodia rutaecarpa in colorectal cancer","volume":"23","author":"Lu Y","year":"2023","unstructured":"Lu Y, Dong K, Yang M, Liu J. Network pharmacology-based strategy to investigate the bioactive ingredients and molecular mechanism of Evodia rutaecarpa in colorectal cancer. BMC Complement Med Ther. 2023, 23:433. 10.1186\/s12906-023-04254-8","journal-title":"BMC Complement Med Ther"},{"key":"ref58","doi-asserted-by":"publisher","DOI":"10.2174\/1568026618666180330141351","article-title":"Network pharmacology: exploring the resources and methodologies","volume":"18","author":"Muhammad J","year":"2018","unstructured":"Muhammad J, Khan A, Ali A, Fang L, Yanjing W, Xu Q, Wei DQ. Network pharmacology: exploring the resources and methodologies. Curr Top Med Chem. 2018, 18:949-64. 10.2174\/1568026618666180330141351","journal-title":"Curr Top Med Chem"},{"key":"ref59","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/7697356","article-title":"Systems pharmacology-based approach of connecting disease genes in genome-wide association studies with traditional Chinese medicine","volume":"2018","author":"Kim J","year":"2018","unstructured":"Kim J, Yoo M, Shin J, Kim H, Kang J, Tan AC. Systems pharmacology-based approach of connecting disease genes in genome-wide association studies with traditional Chinese medicine. Int J Genomics. 2018, 2018:7697356. 10.1155\/2018\/7697356","journal-title":"Int J Genomics"},{"key":"ref60","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-12366-3","article-title":"Network pharmacology combined with GEO database identifying the mechanisms and molecular targets of Polygoni Cuspidati Rhizoma on peri-implants","volume":"12","author":"Shan C","year":"2022","unstructured":"Shan C, Ji X, Wu Z, Zhao J. Network pharmacology combined with GEO database identifying the mechanisms and molecular targets of Polygoni Cuspidati Rhizoma on peri-implants. Sci Rep. 2022, 12:8227. 10.1038\/s41598-022-12366-3","journal-title":"Sci Rep"},{"key":"ref61","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.1058780","article-title":"Integration of network pharmacology and molecular docking to explore the molecular mechanism of Cordycepin in the treatment of Alzheimer's disease","volume":"14","author":"Ma X","year":"2022","unstructured":"Ma X, Zhao Y, Yang T, Gong N, Chen X, Liu G, Xiao J. Integration of network pharmacology and molecular docking to explore the molecular mechanism of Cordycepin in the treatment of Alzheimer's disease. Front Aging Neurosci. 2022, 14:1058780. 10.3389\/fnagi.2022.1058780","journal-title":"Front Aging Neurosci"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-022-00327-y","article-title":"Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients","volume":"6","author":"de Bitter TJ","year":"2022","unstructured":"de Bitter TJ, de Reuver PR, de Savornin Lohman EA, et al.. Comprehensive clinicopathological and genomic profiling of gallbladder cancer reveals actionable targets in half of patients. NPJ Precis Oncol. 2022, 6:83. 10.1038\/s41698-022-00327-y","journal-title":"NPJ Precis Oncol"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1177\/1176935120922154","article-title":"Identification of altered genes in gallbladder cancer as potential driver mutations for diagnostic and prognostic purposes: a computational approach","volume":"19","author":"D'Afonseca V","year":"2020","unstructured":"D'Afonseca V, Arencibia AD, Echeverr\u00eda-Vega A, et al.. Identification of altered genes in gallbladder cancer as potential driver mutations for diagnostic and prognostic purposes: a computational approach. Cancer Inform. 2020, 19:1176935120922154. 10.1177\/1176935120922154","journal-title":"Cancer Inform"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-1954","article-title":"Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention","volume":"28","author":"Giraldo NA","year":"2022","unstructured":"Giraldo NA, Drill E, Satravada BA, et al.. Comprehensive molecular characterization of gallbladder carcinoma and potential targets for intervention. Clin Cancer Res. 2022, 28:5359-67. 10.1158\/1078-0432.CCR-22-1954","journal-title":"Clin Cancer Res"},{"key":"ref65","doi-asserted-by":"publisher","DOI":"10.1038\/s41596-018-0103-9","article-title":"Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap","volume":"14","author":"Reimand J","year":"2019","unstructured":"Reimand J, Isserlin R, Voisin V, et al.. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap. Nat Protoc. 2019, 14:482-517. 10.1038\/s41596-018-0103-9","journal-title":"Nat Protoc"},{"key":"ref66","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1010348","article-title":"Nine quick tips for pathway enrichment analysis","volume":"18","author":"Chicco D","year":"2022","unstructured":"Chicco D, Agapito G. Nine quick tips for pathway enrichment analysis. PLoS Comput Biol. 2022, 18:e1010348. 10.1371\/journal.pcbi.1010348","journal-title":"PLoS Comput Biol"},{"key":"ref67","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac355","article-title":"Systematic assessment of pathway databases, based on a diverse collection of user-submitted experiments","volume":"23","author":"Gable AL","year":"2022","unstructured":"Gable AL, Szklarczyk D, Lyon D, Matias Rodrigues JF, von Mering C. Systematic assessment of pathway databases, based on a diverse collection of user-submitted experiments. Brief Bioinform. 2022, 23:bbac355. 10.1093\/bib\/bbac355","journal-title":"Brief Bioinform"},{"key":"ref68","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btz931","article-title":"ShinyGO: a graphical gene-set enrichment tool for animals and plants","volume":"36","author":"Ge SX","year":"2020","unstructured":"Ge SX, Jung D, Yao R. ShinyGO: a graphical gene-set enrichment tool for animals and plants. Bioinformatics. 2020, 36:2628-9. 10.1093\/bioinformatics\/btz931","journal-title":"Bioinformatics"},{"key":"ref69","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1209-1135","article-title":"How does multiple testing correction work?","volume":"27","author":"Noble WS","year":"2009","unstructured":"Noble WS. How does multiple testing correction work?. Nat Biotechnol. 2009, 27:1135-7. 10.1038\/nbt1209-1135","journal-title":"Nat Biotechnol"},{"key":"ref70","doi-asserted-by":"publisher","DOI":"10.1186\/s40643-024-00764-6","article-title":"Network pharmacology and molecular docking: combined computational approaches to explore the antihypertensive potential of Fabaceae species","volume":"11","author":"Shahzadi Z","year":"2024","unstructured":"Shahzadi Z, Yousaf Z, Anjum I, et al.. Network pharmacology and molecular docking: combined computational approaches to explore the antihypertensive potential of Fabaceae species. Bioresour Bioprocess. 2024, 11:53. 10.1186\/s40643-024-00764-6","journal-title":"Bioresour Bioprocess"},{"key":"ref71","doi-asserted-by":"publisher","DOI":"10.1002\/fsn3.71287","article-title":"Network pharmacology, molecular docking, and molecular dynamics simulations to elucidate the potential mechanism of Ermiao San in osteoarthritis","volume":"13","author":"Song Z","year":"2025","unstructured":"Song Z, Huang J, Zhu H, et al.. Network pharmacology, molecular docking, and molecular dynamics simulations to elucidate the potential mechanism of Ermiao San in osteoarthritis. Food Sci Nutr. 2025, 13:e71287. 10.1002\/fsn3.71287","journal-title":"Food Sci Nutr"},{"key":"ref72","doi-asserted-by":"publisher","DOI":"10.1021\/ci800293n","article-title":"Validation of molecular docking programs for virtual screening against dihydropteroate synthase","volume":"49","author":"Hevener KE","year":"2009","unstructured":"Hevener KE, Zhao W, Ball DM, Babaoglu K, Qi J, White SW, Lee RE. Validation of molecular docking programs for virtual screening against dihydropteroate synthase. J Chem Inf Model. 2009, 49:444-60. 10.1021\/ci800293n","journal-title":"J Chem Inf Model"},{"key":"ref73","doi-asserted-by":"publisher","DOI":"10.33011\/livecoms.4.1.1497","article-title":"Best practices for constructing, preparing, and evaluating protein-ligand binding affinity benchmarks [Article v0.1]","volume":"4","author":"Hahn DF","year":"2022","unstructured":"Hahn DF, Bayly CI, Boby ML, et al.. Best practices for constructing, preparing, and evaluating protein-ligand binding affinity benchmarks [Article v0.1]. Living J Comput Mol Sci. 2022, 4:1497. 10.33011\/livecoms.4.1.1497","journal-title":"Living J Comput Mol Sci"},{"key":"ref74","doi-asserted-by":"publisher","DOI":"10.4310\/cis.241021221101","article-title":"Docking strategies for predicting protein-ligand interactions and their application to structure-based drug design","volume":"24","author":"Ma Z","year":"2024","unstructured":"Ma Z, Ajibade A, Zou X. Docking strategies for predicting protein-ligand interactions and their application to structure-based drug design. Commun Inf Syst. 2024, 24:199-230. 10.4310\/cis.241021221101","journal-title":"Commun Inf Syst"},{"key":"ref75","article-title":"Integrative network-based approaches identified systems-level molecular signatures associated with gallbladder cancer pathogenesis from gallstone diseases","volume":"47","author":"Roy N","year":"2022","unstructured":"Roy N, Dihingia BR, Barah P. Integrative network-based approaches identified systems-level molecular signatures associated with gallbladder cancer pathogenesis from gallstone diseases. J Biosci. 2022, 47:31.","journal-title":"J Biosci"},{"key":"ref76","doi-asserted-by":"publisher","DOI":"10.1080\/17460441.2020.1798926","article-title":"Open access in silico tools to predict the ADMET profiling of drug candidates","volume":"15","author":"Kar S","year":"2020","unstructured":"Kar S, Leszczynski J. Open access in silico tools to predict the ADMET profiling of drug candidates. Expert Opin Drug Discov. 2020, 15:1473-87. 10.1080\/17460441.2020.1798926","journal-title":"Expert Opin Drug Discov"},{"key":"ref77","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2018.00923","article-title":"Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: an overview","volume":"9","author":"Salmaso V","year":"2018","unstructured":"Salmaso V, Moro S. Bridging molecular docking to molecular dynamics in exploring ligand-protein recognition process: an overview. Front Pharmacol. 2018, 9:923. 10.3389\/fphar.2018.00923","journal-title":"Front Pharmacol"},{"key":"ref78","doi-asserted-by":"publisher","DOI":"10.1002\/ptr.7411","article-title":"Network pharmacology reveals potential functional components and underlying molecular mechanisms of Andrographis paniculata in esophageal cancer treatment","volume":"36","author":"Cheung MK","year":"2022","unstructured":"Cheung MK, Yue GG, Gomes AJ, et al.. Network pharmacology reveals potential functional components and underlying molecular mechanisms of Andrographis paniculata in esophageal cancer treatment. Phytother Res. 2022, 36:1748-60. 10.1002\/ptr.7411","journal-title":"Phytother Res"},{"key":"ref79","doi-asserted-by":"publisher","DOI":"10.3390\/cells8030201","article-title":"Complex systems biology approach in connecting PI3K-Akt and NF-\u03baB pathways in prostate cancer","volume":"8","author":"Shankar E","year":"2019","unstructured":"Shankar E, Weis MC, Avva J, Shukla S, Shukla M, Sreenath SN, Gupta S. Complex systems biology approach in connecting PI3K-Akt and NF-\u03baB pathways in prostate cancer. Cells. 2019, 8:201. 10.3390\/cells8030201","journal-title":"Cells"},{"key":"ref80","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/3919143","article-title":"A network pharmacology study on the molecular mechanisms of FDY003 for breast cancer treatment","volume":"2021","author":"Lee HS","year":"2021","unstructured":"Lee HS, Lee IH, Kang K, Park SI, Moon SJ, Lee CH, Lee DY. A network pharmacology study on the molecular mechanisms of FDY003 for breast cancer treatment. Evid Based Complement Alternat Med. 2021, 2021:3919143. 10.1155\/2021\/3919143","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref81","doi-asserted-by":"publisher","DOI":"10.12688\/f1000research.155657.2","article-title":"Molecular docking and MD simulation approach to identify potential phytochemical lead molecule against triple negative breast cancer","volume":"13","author":"Sankaranarayanan P","year":"2024","unstructured":"Sankaranarayanan P, G DJ, Pa A, Manikandan M, Ghosh A. Molecular docking and MD simulation approach to identify potential phytochemical lead molecule against triple negative breast cancer. F1000Res. 2024, 13:1271. 10.12688\/f1000research.155657.2","journal-title":"F1000Res"},{"key":"ref82","doi-asserted-by":"publisher","DOI":"10.5812\/ijpr-162305","article-title":"Integrating network pharmacology and experimental validation to identifying key herbal components and targets for liver cancer","volume":"24","author":"Wang F","year":"2025","unstructured":"Wang F, Li S, Liu X, Xu Y, Yan H. Integrating network pharmacology and experimental validation to identifying key herbal components and targets for liver cancer. Iran J Pharm Res. 2025, 24:e162305. 10.5812\/ijpr-162305","journal-title":"Iran J Pharm Res"},{"key":"ref83","doi-asserted-by":"publisher","DOI":"10.1186\/s13020-021-00423-4","article-title":"Network pharmacology based research into the effect and mechanism of yinchenhao decoction against cholangiocarcinoma","volume":"16","author":"Chen Z","year":"2021","unstructured":"Chen Z, Lin T, Liao X, et al.. Network pharmacology based research into the effect and mechanism of yinchenhao decoction against cholangiocarcinoma. Chin Med. 2021, 16:13. 10.1186\/s13020-021-00423-4","journal-title":"Chin Med"},{"key":"ref84","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v17.i1.101581","article-title":"Network pharmacology: changes the treatment mode of \"one disease-one target\" in cancer treatment","volume":"17","author":"Liu S","year":"2025","unstructured":"Liu S, Yu YW. Network pharmacology: changes the treatment mode of \"one disease-one target\" in cancer treatment. World J Gastrointest Oncol. 2025, 17:101581. 10.4251\/wjgo.v17.i1.101581","journal-title":"World J Gastrointest Oncol"},{"key":"ref85","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2014.12.001","article-title":"Beware of docking!","volume":"36","author":"Chen YC","year":"2015","unstructured":"Chen YC. Beware of docking!. Trends Pharmacol Sci. 2015, 36:78-95. 10.1016\/j.tips.2014.12.001","journal-title":"Trends Pharmacol Sci"},{"key":"ref86","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23081899","article-title":"Binding affinity via docking: fact and fiction","volume":"23","author":"Pantsar T","year":"2018","unstructured":"Pantsar T, Poso A. Binding affinity via docking: fact and fiction. Molecules. 2018, 23:1899. 10.3390\/molecules23081899","journal-title":"Molecules"},{"key":"ref87","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17040525","article-title":"Is it reliable to use common molecular docking methods for comparing the binding affinities of enantiomer pairs for their protein target?","volume":"17","author":"Ram\u00edrez D","year":"2016","unstructured":"Ram\u00edrez D, Caballero J. Is it reliable to use common molecular docking methods for comparing the binding affinities of enantiomer pairs for their protein target?. Int J Mol Sci. 2016, 17:525. 10.3390\/ijms17040525","journal-title":"Int J Mol Sci"},{"key":"ref88","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2025.1658462","article-title":"Identification of novel therapeutic targets and effective anticancer agents for gallbladder cancer by integrating bioinformatics analysis and experimental validation","volume":"16","author":"Zhong Y","year":"2025","unstructured":"Zhong Y, Zou R, Luo X, Yang S, He Z, Hu H, Li F. Identification of novel therapeutic targets and effective anticancer agents for gallbladder cancer by integrating bioinformatics analysis and experimental validation. Front Pharmacol. 2025, 16:1658462. 10.3389\/fphar.2025.1658462","journal-title":"Front Pharmacol"},{"key":"ref89","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics15031014","article-title":"In silico pharmacology for evidence-based and precision medicine","volume":"15","author":"Spanakis M","year":"2023","unstructured":"Spanakis M. In silico pharmacology for evidence-based and precision medicine. Pharmaceutics. 2023, 15:1014. 10.3390\/pharmaceutics15031014","journal-title":"Pharmaceutics"},{"key":"ref90","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2024.1406883","article-title":"Editorial: Investigation of the biological properties of natural products using experimental approaches and in silico methods","volume":"12","author":"Mali SN","year":"2024","unstructured":"Mali SN, Dos Santos CB, Campos Rosa J, Neves Cruz J. Editorial: Investigation of the biological properties of natural products using experimental approaches and in silico methods. Front Chem. 2024, 12:1406883. 10.3389\/fchem.2024.1406883","journal-title":"Front Chem"},{"key":"ref91","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbad344","article-title":"Comparative study of the mechanism of natural compounds with similar structures using docking and transcriptome data for improving in silico herbal medicine experimentations","volume":"24","author":"Park M","year":"2023","unstructured":"Park M, Baek SJ, Park SM, Yi JM, Cha S. Comparative study of the mechanism of natural compounds with similar structures using docking and transcriptome data for improving in silico herbal medicine experimentations. Brief Bioinform. 2023, 24:bbad344. 10.1093\/bib\/bbad344","journal-title":"Brief Bioinform"},{"key":"ref92","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2025.104567","article-title":"In silico drug discovery: bridging the gaps in preclinical translation","volume":"31","author":"Markossian S","year":"2026","unstructured":"Markossian S, Baskir HM, Grossman AC, et al.. In silico drug discovery: bridging the gaps in preclinical translation. Drug Discov Today. 2026, 31:104567. 10.1016\/j.drudis.2025.104567","journal-title":"Drug Discov Today"},{"key":"ref93","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2016.00015","article-title":"How reliable are ligand-centric methods for target fishing?","volume":"4","author":"Pe\u00f3n A","year":"2016","unstructured":"Pe\u00f3n A, Dang CC, Ballester PJ. How reliable are ligand-centric methods for target fishing?. Front Chem. 2016, 4:15. 10.3389\/fchem.2016.00015","journal-title":"Front Chem"},{"key":"ref94","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37572-z","article-title":"Improving the generalizability of protein-ligand binding predictions with AI-Bind","volume":"14","author":"Chatterjee A","year":"2023","unstructured":"Chatterjee A, Walters R, Shafi Z, et al.. Improving the generalizability of protein-ligand binding predictions with AI-Bind. Nat Commun. 2023, 14:1989. 10.1038\/s41467-023-37572-z","journal-title":"Nat Commun"},{"key":"ref95","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27092980","article-title":"UnbiasedDTI: mitigating real-world bias of drug-target interaction prediction by using deep ensemble-balanced learning","volume":"27","author":"Tayebi A","year":"2022","unstructured":"Tayebi A, Yousefi N, Yazdani-Jahromi M, Kolanthai E, Neal CJ, Seal S, Garibay OO. UnbiasedDTI: mitigating real-world bias of drug-target interaction prediction by using deep ensemble-balanced learning. Molecules. 2022, 27:2980. 10.3390\/molecules27092980","journal-title":"Molecules"},{"key":"ref96","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13215257","article-title":"Gallbladder cancer: current insights in genetic alterations and their possible therapeutic implications","volume":"13","author":"Kuipers H","year":"2021","unstructured":"Kuipers H, de Bitter TJ, de Boer MT, et al.. Gallbladder cancer: current insights in genetic alterations and their possible therapeutic implications. Cancers (Basel). 2021, 13:5257. 10.3390\/cancers13215257","journal-title":"Cancers (Basel)"},{"key":"ref97","article-title":"Biases of drug-target interaction network data","author":"Van Laarhoven T","year":"2014","unstructured":"Van Laarhoven T, Marchiori E. Biases of drug-target interaction network data. Pattern Recognition in Bioinformatics. Comin M, K\u00e4ll L, Marchiori E, Ngom A, Rajapakse J (ed): Springer , Cham, Switzerland; 2014. 8626:23-33."},{"key":"ref98","doi-asserted-by":"publisher","DOI":"10.1038\/srep11638","article-title":"Chemical and metabolic profiling of Si-Ni decoction analogous formulae by high performance liquid chromatography-mass spectrometry","volume":"5","author":"Chen Q","year":"2015","unstructured":"Chen Q, Xiao S, Li Z, Ai N, Fan X. Chemical and metabolic profiling of Si-Ni decoction analogous formulae by high performance liquid chromatography-mass spectrometry. Sci Rep. 2015, 5:11638. 10.1038\/srep11638","journal-title":"Sci Rep"},{"key":"ref99","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1322751","article-title":"Chemical characterization and metabolic profiling of the compounds in the Chinese herbal formula Li Chang decoction by UPLC-QTOF\/MS","volume":"2022","author":"Lin B","year":"2022","unstructured":"Lin B, Guo S, Hong X, et al.. Chemical characterization and metabolic profiling of the compounds in the Chinese herbal formula Li Chang decoction by UPLC-QTOF\/MS. Evid Based Complement Alternat Med. 2022, 2022:1322751. 10.1155\/2022\/1322751","journal-title":"Evid Based Complement Alternat Med"},{"key":"ref100","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2015.01.009","article-title":"The application of in silico drug-likeness predictions in pharmaceutical research","volume":"86","author":"Tian S","year":"2015","unstructured":"Tian S, Wang J, Li Y, Li D, Xu L, Hou T. The application of in silico drug-likeness predictions in pharmaceutical research. Adv Drug Deliv Rev. 2015, 86:2-10. 10.1016\/j.addr.2015.01.009","journal-title":"Adv Drug Deliv Rev"},{"key":"ref101","doi-asserted-by":"publisher","DOI":"10.1016\/S1574-1400(05)01011-X","article-title":"Capter 11 Filtering in drug discovery","volume":"1","author":"Lipinski CA","year":"2005","unstructured":"Lipinski CA. Capter 11 Filtering in drug discovery. Annu Rep Comput Chem. 2005, 1:155-68. 10.1016\/S1574-1400(05)01011-X","journal-title":"Annu Rep Comput Chem"},{"key":"ref102","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2016.00375","article-title":"Evolution of centrality measurements for the detection of essential proteins in biological networks","volume":"7","author":"Jalili M","year":"2016","unstructured":"Jalili M, Salehzadeh-Yazdi A, Gupta S, Wolkenhauer O, Yaghmaie M, Resendis-Antonio O, Alimoghaddam K. Evolution of centrality measurements for the detection of essential proteins in biological networks. Front Physiol. 2016, 7:375. 10.3389\/fphys.2016.00375","journal-title":"Front Physiol"},{"key":"ref103","doi-asserted-by":"publisher","DOI":"10.4137\/grsb.s702","article-title":"Centrality analysis methods for biological networks and their application to gene regulatory networks","volume":"2","author":"Kosch\u00fctzki D","year":"2008","unstructured":"Kosch\u00fctzki D, Schreiber F. Centrality analysis methods for biological networks and their application to gene regulatory networks. Gene Regul Syst Bio. 2008, 2:193-201. 10.4137\/grsb.s702","journal-title":"Gene Regul Syst Bio"},{"key":"ref104","doi-asserted-by":"publisher","DOI":"10.1093\/bib\/bbac143","article-title":"On the influence of several factors on pathway enrichment analysis","volume":"23","author":"Mubeen S","year":"2022","unstructured":"Mubeen S, Tom Kodamullil A, Hofmann-Apitius M, Domingo-Fern\u00e1ndez D. On the influence of several factors on pathway enrichment analysis. Brief Bioinform. 2022, 23:bbac143. 10.1093\/bib\/bbac143","journal-title":"Brief Bioinform"},{"key":"ref105","doi-asserted-by":"publisher","DOI":"10.1016\/j.compbiolchem.2021.107455","article-title":"Beyond standard pipeline and p\u202f<\u202f0.05 in pathway enrichment analyses","volume":"92","author":"Li W","year":"2021","unstructured":"Li W, Shih A, Freudenberg-Hua Y, Fury W, Yang Y. Beyond standard pipeline and p\u202f&lt;\u202f0.05 in pathway enrichment analyses. Comput Biol Chem. 2021, 92:107455. 10.1016\/j.compbiolchem.2021.107455","journal-title":"Comput Biol Chem"},{"key":"ref106","doi-asserted-by":"publisher","DOI":"10.1021\/jm0608356","article-title":"Benchmarking sets for molecular docking","volume":"49","author":"Huang N","year":"2006","unstructured":"Huang N, Shoichet BK, Irwin JJ. Benchmarking sets for molecular docking. J Med Chem. 2006, 49:6789-801. 10.1021\/jm0608356","journal-title":"J Med Chem"},{"key":"ref107","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.7b00277","article-title":"ProSelection: a novel algorithm to select proper protein structure subsets for in silico target identification and drug discovery research","volume":"57","author":"Wang N","year":"2017","unstructured":"Wang N, Wang L, Xie XQ. ProSelection: a novel algorithm to select proper protein structure subsets for in silico target identification and drug discovery research. J Chem Inf Model. 2017, 57:2686-98. 10.1021\/acs.jcim.7b00277","journal-title":"J Chem Inf Model"},{"key":"ref108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21207708","article-title":"Setup and validation of a reliable docking protocol for the development of neuroprotective agents by targeting the sigma-1 receptor (S1R)","volume":"21","author":"Rossino G","year":"2020","unstructured":"Rossino G, Rui M, Pozzetti L, et al.. Setup and validation of a reliable docking protocol for the development of neuroprotective agents by targeting the sigma-1 receptor (S1R). Int J Mol Sci. 2020, 21:7708. 10.3390\/ijms21207708","journal-title":"Int J Mol Sci"},{"key":"ref109","doi-asserted-by":"publisher","DOI":"10.1186\/s12906-024-04518-x","article-title":"Integrating network pharmacology, bioinformatics, and experimental validation to unveil the molecular targets and mechanisms of galangin for treating hepatocellular carcinoma","volume":"24","author":"Li X","year":"2024","unstructured":"Li X, Zhou M, Chen W, et al.. Integrating network pharmacology, bioinformatics, and experimental validation to unveil the molecular targets and mechanisms of galangin for treating hepatocellular carcinoma. BMC Complement Med Ther. 2024, 24:208. 10.1186\/s12906-024-04518-x","journal-title":"BMC Complement Med Ther"},{"key":"ref110","doi-asserted-by":"publisher","DOI":"10.2174\/0113895575258033231024073521","article-title":"In silico pharmacokinetics, molecular docking and molecular dynamics simulation studies of nucleoside analogs for drug discovery- a mini review","volume":"24","author":"Kawsar SM","year":"2024","unstructured":"Kawsar SM, Munia NS, Saha S, Ozeki Y. In silico pharmacokinetics, molecular docking and molecular dynamics simulation studies of nucleoside analogs for drug discovery- a mini review. Mini Rev Med Chem. 2024, 24:1070-88. 10.2174\/0113895575258033231024073521","journal-title":"Mini Rev Med Chem"},{"key":"ref111","doi-asserted-by":"publisher","DOI":"10.1111\/bph.15054","article-title":"A practical guide for transparent reporting of research on natural products in the British Journal of Pharmacology: reproducibility of natural product research","volume":"177","author":"Izzo AA","year":"2020","unstructured":"Izzo AA, Teixeira M, Alexander SP, et al.. A practical guide for transparent reporting of research on natural products in the British Journal of Pharmacology: reproducibility of natural product research. Br J Pharmacol. 2020, 177:2169-78. 10.1111\/bph.15054","journal-title":"Br J Pharmacol"},{"key":"ref112","doi-asserted-by":"publisher","DOI":"10.1038\/sdata.2016.18","article-title":"The FAIR guiding principles for scientific data management and stewardship","volume":"3","author":"Wilkinson MD","year":"2016","unstructured":"Wilkinson MD, Dumontier M, Aalbersberg IJ, et al.. The FAIR guiding principles for scientific data management and stewardship. Sci Data. 2016, 3:160018. 10.1038\/sdata.2016.18","journal-title":"Sci Data"},{"key":"ref113","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-014-0241-z","article-title":"Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement","volume":"13","author":"Collins GS","year":"2015","unstructured":"Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMC Med. 2015, 13:1. 10.1186\/s12916-014-0241-z","journal-title":"BMC Med"},{"key":"ref114","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-025-19931-6","article-title":"Integrating in-silico and experimental validation approaches to unveil the therapeutic mechanism of naringenin against breast cancer","volume":"15","author":"Mir SA","year":"2025","unstructured":"Mir SA, Bhat BA, Hamid L, et al.. Integrating in-silico and experimental validation approaches to unveil the therapeutic mechanism of naringenin against breast cancer. Sci Rep. 2025, 15:36035. 10.1038\/s41598-025-19931-6","journal-title":"Sci Rep"},{"key":"ref115","doi-asserted-by":"publisher","DOI":"10.1007\/s13237-022-00405-3","article-title":"Plant-derived natural products for drug discovery: current approaches and prospects","volume":"65","author":"Nasim N","year":"2022","unstructured":"Nasim N, Sandeep IS, Mohanty S. Plant-derived natural products for drug discovery: current approaches and prospects. Nucleus (Calcutta). 2022, 65:399-411. 10.1007\/s13237-022-00405-3","journal-title":"Nucleus (Calcutta)"},{"key":"ref116","doi-asserted-by":"publisher","DOI":"10.3389\/fchem.2021.761609","article-title":"Currently available strategies for target identification of bioactive natural products","volume":"9","author":"Li G","year":"2021","unstructured":"Li G, Peng X, Guo Y, Gong S, Cao S, Qiu F. Currently available strategies for target identification of bioactive natural products. Front Chem. 2021, 9:761609. 10.3389\/fchem.2021.761609","journal-title":"Front Chem"},{"key":"ref117","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/5313050","article-title":"Statistical approaches for the construction and interpretation of human protein-protein interaction network","volume":"2016","author":"Hu Y","year":"2016","unstructured":"Hu Y, Zhang Y, Ren J, Wang Y, Wang Z, Zhang J. Statistical approaches for the construction and interpretation of human protein-protein interaction network. Biomed Res Int. 2016, 2016:5313050. 10.1155\/2016\/5313050","journal-title":"Biomed Res Int"},{"key":"ref118","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btp465","article-title":"Network analyses in systems pharmacology","volume":"25","author":"Berger SI","year":"2009","unstructured":"Berger SI, Iyengar R. Network analyses in systems pharmacology. Bioinformatics. 2009, 25:2466-72. 10.1093\/bioinformatics\/btp465","journal-title":"Bioinformatics"},{"key":"ref119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pcbi.1009935","article-title":"Urgent need for consistent standards in functional enrichment analysis","volume":"18","author":"Wijesooriya K","year":"2022","unstructured":"Wijesooriya K, Jadaan SA, Perera KL, Kaur T, Ziemann M. Urgent need for consistent standards in functional enrichment analysis. PLoS Comput Biol. 2022, 18:e1009935. 10.1371\/journal.pcbi.1009935","journal-title":"PLoS Comput Biol"},{"key":"ref120","doi-asserted-by":"publisher","DOI":"10.1002\/prot.25875","article-title":"How to choose templates for modeling of protein complexes: insights from benchmarking template-based docking","volume":"88","author":"Chakravarty D","year":"2020","unstructured":"Chakravarty D, McElfresh GW, Kundrotas PJ, Vakser IA. How to choose templates for modeling of protein complexes: insights from benchmarking template-based docking. Proteins. 2020, 88:1070-81. 10.1002\/prot.25875","journal-title":"Proteins"},{"key":"ref121","doi-asserted-by":"publisher","DOI":"10.3390\/ijms11083016","article-title":"Advances and challenges in protein-ligand docking","volume":"11","author":"Huang SY","year":"2010","unstructured":"Huang SY, Zou X. Advances and challenges in protein-ligand docking. Int J Mol Sci. 2010, 11:3016-34. 10.3390\/ijms11083016","journal-title":"Int J Mol Sci"},{"key":"ref122","doi-asserted-by":"publisher","DOI":"10.3390\/molecules190710150","article-title":"Challenges, applications, and recent advances of protein-ligand docking in structure-based drug design","volume":"19","author":"Grinter SZ","year":"2014","unstructured":"Grinter SZ, Zou X. Challenges, applications, and recent advances of protein-ligand docking in structure-based drug design. Molecules. 2014, 19:10150-76. 10.3390\/molecules190710150","journal-title":"Molecules"},{"key":"ref123","doi-asserted-by":"publisher","DOI":"10.2174\/138920012800840419","article-title":"Physiologically based pharmacokinetic models: integration of in silico approaches with micro cell culture analogues","volume":"13","author":"Chen A","year":"2012","unstructured":"Chen A, Yarmush ML, Maguire T. Physiologically based pharmacokinetic models: integration of in silico approaches with micro cell culture analogues. Curr Drug Metab. 2012, 13:863-80. 10.2174\/138920012800840419","journal-title":"Curr Drug Metab"},{"key":"ref124","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-89257-6","article-title":"Network pharmacology integrated with experimental validation revealed the anti-inflammatory effects of Andrographis paniculata","volume":"11","author":"Zhu N","year":"2021","unstructured":"Zhu N, Hou J, Yang N. Network pharmacology integrated with experimental validation revealed the anti-inflammatory effects of Andrographis paniculata. Sci Rep. 2021, 11:9752. 10.1038\/s41598-021-89257-6","journal-title":"Sci Rep"},{"key":"ref125","doi-asserted-by":"publisher","DOI":"10.3390\/life15121828","article-title":"Computational investigation identifies mTOR as a primary binding target of medicarpin in cholangiocarcinoma: insights from network pharmacology and molecular docking","volume":"15","author":"Sitthirak S","year":"2025","unstructured":"Sitthirak S, Tedasen A, Rattanapan Y, et al.. Computational investigation identifies mTOR as a primary binding target of medicarpin in cholangiocarcinoma: insights from network pharmacology and molecular docking. Life (Basel). 2025, 15:1828. 10.3390\/life15121828","journal-title":"Life (Basel)"},{"key":"ref126","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1116532","article-title":"Plant-derived natural products and combination therapy in liver cancer","volume":"13","author":"Wang Y","year":"2023","unstructured":"Wang Y, Li J, Xia L. Plant-derived natural products and combination therapy in liver cancer. Front Oncol. 2023, 13:1116532. 10.3389\/fonc.2023.1116532","journal-title":"Front Oncol"},{"key":"ref127","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4939-8618-7_16","article-title":"Computational network analysis for drug toxicity prediction","author":"Hardt C","year":"2018","unstructured":"Hardt C, Bauer C, Schuchhardt J, Herwig R. Computational network analysis for drug toxicity prediction. Computational Cell Biology. Methods in Molecular Biology. von Stechow L, Santos Delgado A (ed):  Humana Press, New York, NY; 2018. 10.1007\/978-1-4939-8618-7_16"},{"key":"ref128","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2019.00557","article-title":"Natural product target network reveals potential for cancer combination therapies","volume":"10","author":"Chamberlin SR","year":"2019","unstructured":"Chamberlin SR, Blucher A, Wu G, Shinto L, Choonoo G, Kulesz-Martin M, McWeeney S. Natural product target network reveals potential for cancer combination therapies. Front Pharmacol. 2019, 10:557. 10.3389\/fphar.2019.00557","journal-title":"Front Pharmacol"},{"key":"ref129","doi-asserted-by":"publisher","DOI":"10.2174\/157340911795677602","article-title":"Molecular docking: a powerful approach for structure-based drug discovery","volume":"7","author":"Meng XY","year":"2011","unstructured":"Meng XY, Zhang HX, Mezei M, Cui M. Molecular docking: a powerful approach for structure-based drug discovery. Curr Comput Aided Drug Des. 2011, 7:146-57. 10.2174\/157340911795677602","journal-title":"Curr Comput Aided Drug Des"},{"key":"ref130","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1129709","article-title":"Uncovering the mechanism of Kang-ai injection for treating intrahepatic cholangiocarcinoma based on network pharmacology, molecular docking, and in vitro validation","volume":"14","author":"Song F","year":"2023","unstructured":"Song F, Lu CL, Wang CG, et al.. Uncovering the mechanism of Kang-ai injection for treating intrahepatic cholangiocarcinoma based on network pharmacology, molecular docking, and in vitro validation. Front Pharmacol. 2023, 14:1129709. 10.3389\/fphar.2023.1129709","journal-title":"Front Pharmacol"},{"key":"ref131","doi-asserted-by":"publisher","DOI":"10.1007\/s10822-025-00742-w","article-title":"In silico discovery and experimental validation of natural derivatives as inhibitor of phosphoinositide Kinase, PIKfyve","volume":"40","author":"Agarwal V","year":"2025","unstructured":"Agarwal V, Rathore V, Chaudhary A, et al.. In silico discovery and experimental validation of natural derivatives as inhibitor of phosphoinositide Kinase, PIKfyve. J Comput Aided Mol Des. 2025, 40:30. 10.1007\/s10822-025-00742-w","journal-title":"J Comput Aided Mol Des"},{"key":"ref132","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jcim.6b00355","article-title":"Boosting docking-based virtual screening with deep learning","volume":"56","author":"Pereira JC","year":"2016","unstructured":"Pereira JC, Caffarena ER, Dos Santos CN. Boosting docking-based virtual screening with deep learning. J Chem Inf Model. 2016, 56:2495-506. 10.1021\/acs.jcim.6b00355","journal-title":"J Chem Inf Model"},{"key":"ref133","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2020.10.010","article-title":"Artificial intelligence in drug discovery and development","volume":"26","author":"Paul D","year":"2021","unstructured":"Paul D, Sanap G, Shenoy S, Kalyane D, Kalia K, Tekade RK. Artificial intelligence in drug discovery and development. Drug Discov Today. 2021, 26:80-93. 10.1016\/j.drudis.2020.10.010","journal-title":"Drug Discov Today"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/499537-network-pharmacology-and-molecular-docking-for-natural-product-based-therapies-in-gallbladder-and-biliary-tract-cancers-workflows-pitfalls-and-translational-opportunities","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:58:50Z","timestamp":1781499530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/499537-network-pharmacology-and-molecular-docking-for-natural-product-based-therapies-in-gallbladder-and-biliary-tract-cancers-workflows-pitfalls-and-translational-opportunities"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,14]]},"references-count":133,"URL":"https:\/\/doi.org\/10.7759\/cureus.110851","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,14]]}}}